Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients

• Published in: Cancer management and research 2021-01, Vol.13, p.587-593
• Main Authors: Huang, Zhen, Qin, Qinghong, Xia, Longjie, Lian, Bin, Tan, Qixing, Yu, Yinghua, Mo, Qinguo
• Format: Article
• Language: English
• Subjects: Age; Biomarkers; Breast cancer; Cancer therapies; Chemotherapy; Estrogens; Gene expression; long non-coding rna; Lymphatic system; malat1; Metastasis; Neurosciences; oncotype dx 21-gene test; Original Research; risk of recurrence
• ISSN: 1179-1322; 1179-1322
• DOI: 10.2147/CMAR.S276795

To investigate the association between the recurrence score (RS) obtained by Oncotype test and long non-coding RNA (lncRNA) expression in early and estrogen receptor-positive (ER ) breast cancer. The Oncotype test and expression detection were performed in tumor samples from 76 ER and early breast cancer patients with the Surplex liquid chip. The RS value was calculated based on the expression of total 21 genes. The level of was measured in both tumor tissue and para-tumor tissue, and relatively quantified with an internal control gene. Mann-Whitney -test or Kruskal-Wallis test were used to analyze the association between level and different clinical pathological characteristics, including age, tumor stage, disease grade, lymph node status, Ki-67 expression, and progesterone receptor (PR) status. The association between the RS and different characteristics was analyzed by Wilcoxon rank-sum test. Correlation between two parameters was analyzed by Spearman's rank correlation analysis. The expression of was more abundant in tumor tissue (2.992 ± 2.256) than that in adjacent normal tissue (1.641±1.438, =-2.594, 0.009), and it was not correlated with any clinical pathological characteristics. According to the old criteria for RS stratification, 52.7% of patients were in low risk (RS30). While under the new criteria, 18.4% were in low risk group (RS26). The Oncotype results only correlated with Ki-67 expression under both new and old criteria, and it was not related with other cancer characteristics. The expression of lncRNA was significantly correlated with the Oncotype results under the old criteria. is a novel breast cancer biomarker independent of tumor stage, disease grade and lymph node status. level is associated with the Oncotype RS value. Therefore, combination of and the Oncotype test may be used to predict prognosis in ER and early stage breast cancer.